Alladapt Immunotherapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2018-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.alladapt.com
Clinical Trials
2
Active:0
Completed:1
Trial Phases
1 Phases
Phase 1:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (100.0%)Open-label Extension Study of ADP101
Phase 1
Terminated
- Conditions
- Food Allergy
- First Posted Date
- 2022-02-17
- Last Posted Date
- 2024-03-26
- Lead Sponsor
- Alladapt Immunotherapeutics, Inc.
- Target Recruit Count
- 45
- Registration Number
- NCT05243719
- Locations
- 🇺🇸
Study Site, Seattle, Washington, United States
ADP101 for Oral Immunotherapy in Food-Allergic Children and Adults
Phase 1
Completed
- Conditions
- Food Allergy
- First Posted Date
- 2021-04-23
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Alladapt Immunotherapeutics, Inc.
- Target Recruit Count
- 73
- Registration Number
- NCT04856865
- Locations
- 🇺🇸
Study Site, Seattle, Washington, United States
News
No news found